《新股消息》商湯集團:附屬北京商湯被美國列入實體清單
中國最大人工智能軟件公司商湯集團為香港首次公開招股(IPO)提交的文件顯示,其中一間附屬北京商湯,於2019年10月遭美國商務部工業和安全局列入實體清單,限制其購買或以其他方式取得若干商品、軟件及技術的能力,並可能對業務、財務狀況及經營業績產生不利影響。
律師所Hughes Hubbard & Reed的法律意見指出,實體清單許可限制規定企延伸至北京商湯,而不會延伸至實體清單上並無列明的集團其他實體,亦不會延伸至出口管制條例物項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.